Notably, treatment with KC and control tear fluids did not significantly affect pro-MMP9 activity or PLA2G2A levels, but β-estradiol treatment led to a significant upregulation of estrogen receptors (ERα and GPR30). The gene discussed is ESR1; the disease is keratoconus.